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Malaria parasites spend a critical phase of their life cycle inside hepatocytes, in an
environment with complex and distinctive immunological features. Here I will discuss how
the immunological features of the liver and the adaptations of malaria parasites interact,
resulting in defective CD8+ T cell immunity. These processes are explored with a focus
on the mechanism by which CD4+ T cells deliver help to CD8+ T cells, and speciﬁcally
through their interactionwith antigen-presenting cells (APCs), resulting in “licensing” of the
APCs and enhanced capacity to optimally activate CD8+T cells. Synthesis of the available
evidence supports a model in which the parasite-mediated manipulation of programmed
cell death in infected hepatocytes impairs the capacity of the liver’s immune system to
successfully license APCs and fully activate T cell immunity.
Keywords: liver, hepatocyte, malaria parasite, immunity, CD4+ T cell help, CD8+ T cell, antigen-presenting cells,
licensing
INTRODUCTION
Malaria parasites are vulnerable to the mammalian immune sys-
tem from the time they penetrate the skin as sporozoites, during
the passage of these pre-hepatic forms through the blood to the
liver, during their residence inside hepatocytes, and after their
emergence, when they parasitize erythrocytes. In this review, I
consider only immunity to the hepatocellular stage of the parasite.
Liver-stage malaria parasites gain access to hepatocytes by crossing
the liver sinusoidal endothelium, and both direct and indirect evi-
dence suggests that they may exploit Kupffer cells, the liver’s large
resident macrophage population, as portals to gain access to the
underlying Space of Disse, and thus to hepatocytes (Frevert et al.,
2005; Baer et al., 2007).
Once inside the hepatocyte, the malaria parasite establishes a
vacuole, the membrane of which contains both host-derived pro-
teins, and proteins secreted by the parasite. This parasitophorous
vacuole separates the parasite from the host cell cytoplasm, and
acts as the interface through which the parasite subverts cellular
processes to protect it from host defense and to provide a supply
of nutrients. The parasite’s interactions are highly adapted and
successful. Thus, young children infected for the ﬁrst time with
malaria show little resistance, but over time and with repeated
antigen exposure, immunity to the blood-stage gradually estab-
lished sufﬁcient control over parasite growth that the severity of
clinical illness is reduced. However, it is not clear that repeated
infection engenders any immunity against the liver-stage itself.
Therefore, to study immunity to the liver-stage requires the use of
animal models.
While natural immunity to the liver-stage is difﬁcult to detect,
artiﬁcial immunization protocols clearly generate such immunity,
manifest both as reduced parasite load in the liver and as a delay,
or the prevention of blood-stage infection. One approach is to
infect a murine or a human subject with radiation-attenuated
parasites (Hoffman et al., 2002). This approach results in steril-
izing immunity in both species, and in mouse models a variety
of host defenses have been implicated, including innate and
antigen-speciﬁc immune cells (NK cells, CD4+ T cells, CD8+
T cells) and cytokines (IL-12, IFN-gamma; Doolan and Hoffman,
2000). The development of techniques to modify Plasmodium
spp. genes has led to an alternative approach: the development
of genetically attenuated parasites (GAPs). While human trials
are only beginning (Spring et al., 2013), GAP can produce solid
protection in mouse challenge models (Jobe et al., 2007; Trimnell
et al., 2009; Vaughan et al., 2010). Such immunity correlates well
with the capacity of T cells to secrete IFN-gamma, and with CD8+
T cells to kill parasitized hepatocytes in vitro (Trimnell et al., 2009;
Epstein et al., 2011). In principle, a CD8+ T cell can manifest
either or both of these effector functions in vivo; for example in
viral hepatitis B, the major anti-viral effect appears to be due to
IFN-gamma secretion, rather than cytotoxic killing (reviewed in
Guidotti and Chisari, 2001). However, a recent in vivo study shows
that GAP immunization, followed by boosting with a DNA vac-
cine, results in host defense that can destroy in situ hepatocytes that
express malaria-encoded antigens (Chen et al., 2014). These data
support the working hypothesis that the central effector mecha-
nism against liver-stage malaria parasites is cytotoxic killing of the
infected cells by CD8+ cytotoxic T lymphocytes (CTLs), rather
than cytokine-driven intracellular cure of the infection.
THE IMPORTANCE OF HELP
The fundamental immunological problem in liver-stage malaria
is to account for the failure of effective immunity during natu-
ral malaria infection, but the capacity of irradiated sporozoites
and GAP to induce such immunity. The role of CD4+ T cells in
such immunity is complex. Direct antibody-mediated depletion of
CD4+T cells at the time of challenge does not impair anti-malaria
immunity to the liver-stage, implying that at the effector level,
CD8+ CTL are sufﬁcient (Tarun et al., 2007). Yet experiments in
animals that congenitally lack CD4+ T cells are consistent with
the concept that CD4+ T cells are required to prime effective
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immunity (Overstreet et al., 2011). In terms of the biology of
CTL maturation and memory, this makes complete sense. In host
defense against intracellular bacteria, in anti-viral immunity, and
particularly in CD8+ T cell responses against non-inﬂammatory
antigens such as a minor histocompatibility antigens, CD4+ T cell
help is essential, but thenature of the requirement for helpdepends
on the nature of the antigen. Thus, minor histocompatibility anti-
gens require CD4+ T cells to induce an effective CD8+ T cell
response, while other antigens need CD4+ T cells to ensure either
the long-term survival, or the memory effector function of CD8+
T cells (Prlic et al., 2007). There is a rough inverse correlation
between the extent to which the antigen is accompanied by acces-
sory signals, including pathogen-associated molecular patterns
(PAMPs) and damage-associated molecular patterns (DAMPs),
and the extent to which CD4+T cell help is essential for a CD8+T
cell response. In viral hepatitis C, the main cause of immune fail-
ure and chronic infection appears to be the lack of a CD4+ T cell
response, resulting in CD8+ T cells that become exhausted over
time (Thimme et al., 2001; Grakoui et al., 2003; Radziewicz et al.,
2007; Mueller et al., 2010). This same exhausted phenotype in
CD8+ T cells is a major feature of immune failure in many poten-
tially immunogenic cancers (Pardoll, 2012). These diverse diseases
illustrate the central importance of CD4+ T cells in most CD8+
CTL responses; but their precise role in immunity to liver-stage
malaria has yet to be deﬁned.
As a complex parasite, Plasmodium spp. encode diverse non-
mammalian proteins and synthesize many other non-mammalian
molecules that could serve as PAMPs, but during the liver-stage
these molecules could be sequestered inside the parasitophorous
vacuole. However, this is clearly not the case for all CTL target
antigens, since in the context of immunity inducedby either irradi-
ated sporozoites or GAP, infected hepatocytes can be killed. There
is evidence that Plasmodium spp. may actively manage DAMPs,
particularly those associated with cell death. Thus, infection of
mouse hepatocytes with Plasmodium yoelii results in decreased
p53, a mediator of G1 cell cycle checkpoint arrest, and a drug
that sustainedp53 expression reduced infection (Kaushansky et al.,
2013a). The death of hepatocytes infected with wild-type (WT)
parasites was driven bymitochondria and impaired by Bcl-2, while
such control of host cell death appeared to be linked to the presence
of a parasitophorous vacuole (Kaushansky et al., 2013b). Thus it
seems that the parasite ﬁrst delays the division of infected stressed
hepatocytes, then inhibits their death, and ﬁnally allows them
to die via the mitochondrial pathway of apoptosis. All of these
maneuvers may sequester both DAMPS and PAMPs, eliminating
pathways of immune activation.
Together with accessory signals from PAMPs and DAMPs, mat-
uration of an effective CTL response with protective memory
depends on CD4+ T cell help. In the case of malaria liver-
stage antigens, the parasites reside in a cell type that expresses
major histocompatibility complex (MHC) class I, but not MHC
class II. Since CD4+ helper T cells are activated by antigen-
presenting cells (APCs) that express MHC class II, it is clear
that for CD4+ T helper cells to develop, malaria-encoded anti-
gens must be presented by a different cell type, a mechanism
termed cross-presentation; the T cell activation that follows is
cross-priming (Bevan,2006). Cross-presentationmay occur by the
uptake of cellular fragments or soluble proteins, or by the transfer
of complete MHC-antigen complexes (termed: cross-dressing;
Wakim and Bevan, 2011). In the liver, many cell types have the
potential to take up antigen and engage in cross-presentation.
Thus, there are liver-resident and circulating dendritic cells
(DCs), Kupffer cells, liver sinusoidal endothelial cells (LSECs) and
potentially also hepatic stellate cells (Ebrahimkhani et al., 2011).
Among these, liver DCs and LSECs have the strongest credentials
(Berg et al., 2006; Sumpter et al., 2007). Caveats concerning their
role as APCs for liver-stage malaria antigens will be considered
below.
LICENSED VERSUS UNLICENSED HELP
Once a CD4+ T helper cell is activated, help may be delivered
to a CD8+ T cell by several known mechanisms (Lee et al., 2003).
Licensing of theAPCoccurswhen theCD4+Tcell recognizes anti-
gen presented by an MHC class II+ APC, and delivers activating
signals through co-stimulatory pathways, involving such receptors
as CD80,CD86, andCD40 on theAPC and their counter-receptors
on the T cell. These signals activate the APC, resulting it its capac-
ity to deliver enhanced signals to any CD8+ T cell that recognizes
antigen on the same APC (Smith et al., 2004). This mechanism,
though elegant and precise, requires that two relatively rare cells,
the antigen-speciﬁc CD4+ T cell and the antigen-speciﬁc CD8+
T cell, should ﬁnd the same APC, but it does not require that they
should do so at the same time. While recent advances in in vivo
imaging clearly reveal sustained contact between both CD4+ T
cells and CD8+ T cells with DCs, clear evidence for simultaneous
clusters of all three cells is not a striking feature of active immune
responses in lymph nodes (Germain et al., 2012). Licensing also
clearly requires that the APC express MHC class I and MHC class
II, while hepatocytes do not. Abundant evidence suggests that
hepatocyte can act as APC and induce primary activation in naïve
CD8+T cells, both in vitro and in vivo (Bertolino et al., 1998; Klein
and Crispe, 2006), but the lack of MHC class II expression means
that a hepatocyte is an APC that cannot be licensed, even in prin-
ciple. Therefore if anti-malaria CD8+ T cells were to be primed
directly on hepatocytes, they could only receive help through an
alternative mechanism.
Two known possibilities exist to bypass the need for licens-
ing. First, and most simply, the CD4+ T cell may secrete growth
factors such as Interleukin-2 (IL-2) that promote CD8+ T cell
proliferation and maturation. This model is supported by exper-
iments in which CD8+ T cells, selectively deprived of the ability
to respond to IL-2, fail to undergo full differentiation (Williams
et al., 2006). The alternative mechanism through which CD4+ T
cells can deliver help to CD8+ T cells is through a direct interac-
tion that depends on CD40 on the CD8+ T cell, and appears to
be a direct T–T interaction involving on CD40L on the CD4+ T
cell (Isogawa et al., 2013). This mechanism of help allows for the
CD8+ and the CD4+ T cell to interact with different APCs, and
so could overcome the limitations of a CTL target antigen that is
not readily cross-presented.
To understand how fully effective, long-lived CD8+ T cells
might arise in response to Plasmodium-infected hepatocytes, it
is important to know whether these CD8+ T cells are primed
directly on hepatocytes, or via cross-presentation of antigen
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FIGURE 1 |The pathway of liver-stage malaria antigen presentation
constrains the mechanism of CD4+T cells help. 1: Liver-stage antigens
may exit from the parasitophorous vacuole (PV ) in some kind of transport
vesicle (ves), and be directly presented to CD8+ T cells by the infected
hepatocyte. 2: Hepatocyte antigens may be taken up and cross-presented
by neighboring hepatocytes, resulting in cross-presentation to CD8+ T cells.
However, hepatocytes do not express MHC class II, and so cannot be
licensed. This presents an obstacle to the delivery of CD4+ T cell help to
these CD8+ T cells. 3: Malaria liver-stage antigens may be cross-presented
by liver sinusoidal endothelial cells (LSEC ), either by direct cell-to-cell
transfer or via antigen-containing exosomes (exo). Since the LSEC expresses
both MHC class I and class II, it can be licensed, facilitating CD4+ T cell
help for the CD8+ T cell. 4: At the time of death of the infected hepatocyte
and merozoite release, antigens may be cross-presented by myeloid cells,
including liver-resident Kupffer cells (KC ) and recirculating dendritic cells
(DC ). These cells also express MHC class I and class II, and are optimized to
transmit CD4+ T cell help for CD8+ T cells through the licensing
mechanism.
by an APC that can be licensed. There is some circumstan-
tial evidence that cross-presentation of hepatocellular antigens is
constrained. First, in experimental delivery of antigen to hepato-
cytes using an adeno-associated virus (AAV) vector, the activation
of antigen-speciﬁc CD8+ T cells was exclusively via non-bone
marrow-derived APC, consistent with direct-priming (Wuen-
sch et al., 2010). Second, in a liver transplant patient infected
with Hepatitis C, new CTL appeared that were restricted to
the human leukocyte antigen (HLA) of the liver donor, imply-
ing that they were primed on a solid tissue and not on bone
marrow-derived DCs (Lauer, 2005). Third, when hepatocytes
undergo apoptotic death, a major pathway of their disposal is
phagocytosis by other hepatocytes (Dini et al., 1992; Dalton et al.,
2003), which would keep any pathogen-encoded antigens within
the hepatocyte pool. These considerations render it plausible
that hepatocellular antigens are limited in their susceptibility to
cross-presentation.
However, these experiments are subject to the caveat that LSECs
are non-bone marrow-derived APCs that are not replaced with
host-derived cells after a liver transplant. They are efﬁcient in
antigen uptake, and fully competent to cross-present both hepato-
cyte antigens and cancer cell-derived antigens in vitro (Berg et al.,
2006; Ebrahimkhani et al., 2011). Furthermore these cells express
both MHC class I and MHC class II, and so could potentially be
licensed. In vitro, the activation of CD8+ T cells by LSECs typ-
ically leads to tolerance, but this could be in their un-licensed
state; antigen recognition by a CD4+ T cell on an LSEC could
result in licensing, with a changed outcome and complete activa-
tion when a CD8+ T cell interacts with the same LSEC. Kupffer
cells occupy a rather similar position, since they are MHC class I+
II+macrophages, and a subset of them termed sessile Kupffer cells
are both radiation-resistant, and persistent after a liver transplant
(Kennedy and Abkowitz, 1997; Klein et al., 2007). In vitro, Kupffer
cell also induce abortive T cell activation leading to tolerance, but
explicit experiments to license these cells via CD4+ T cell help,
and then test their capacity to prime CD8+ T cells, have not been
attempted.
THE ROOTS OF HELPLESSNESS
The mechanisms of direct versus cross-presentation, CD4+ T cell
priming and the delivery of help via licensed APCs or otherwise
collectively deﬁne the problem with respect to liver-stage malaria
vaccine strategies (Figure 1). Any of the constraints that limit
effective delivery of CD4+ T cell help to CD8+ T cells could apply
in the context of natural malaria infection, but be circumvented
by irradiated sporozoites or GAP vaccines.
First, viable malaria parasites could facilitate the death of the
infected hepatocyte by a mechanism that favors the containment
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of PAMPs and DAMPs. Either irradiated sporozoites, or GAP that
act as live-attenuated vaccines, may lose this ability. This would
have the effect of rendering malaria antigen-speciﬁc CD8+ T
cells highly help-dependent due to the limited PAMP and DAMP
signals. Second, the hepatocytes that are infected by wild-type
parasites could undergo death in a manner that facilitates uptake
by neighboring hepatocytes. Hepatocytes are surprisingly phago-
cytic. They can take up activatedCD8+T cells and destroy them in
a mechanism of tolerance termed suicidal emperipolesis (Benseler
et al., 2011); and they can take up apoptotic hepatocytes through
a mechanism that depends on the asialo-glycoprotein receptor
(McVicker et al., 2002; Dalton et al., 2003). Such uptake would
tend to contain parasite-encoded antigens within an APC that
can engage CD8+ T cells, but cannot be licensed, resulting in
impaired susceptibility to CD4+T cell help. It is then possible that
irradiated sporozoites or GAP result in hepatocyte death from a
different mechanism, such as pyroptosis or necroptosis, that facil-
itates cross-presentation by other cell types. So far these issues
have been considered in cancer, where many anti-cancer drugs kill
cancer cells by diverse mechanism that may inﬂuence antigen pre-
sentation (Guo et al., 2014); but the principle is likely to apply also
to infectious disease, in particularmalaria parasites in hepatocytes.
In addition to regulation at the levels of antigen recogni-
tion and APC licensing, T cell immune responses, including
the responses to many hepatocellular pathogens, are regulated
through multiple classes of inhibitors molecules, including co-
inhibitory signals such as PD-L1 and Galectin-9 that interact with
counter-receptors (PD-1, and Tim3 respectively) on the T cells;
and immune suppressive small molecules such as kynurenine, the
product of tryptophan breakdown by the enzyme indoleamine
2,3-dioxygenase (IDO), and prostaglandin-E2, which is made in
immunosuppressivemacrophages by an enzyme cascade involving
cyclo-oxygenase type -2 (COX2; reviewed inCrispe, 2014). Several
of these mechanisms have already been implicated in resistance to
blood-stage malaria infection (Butler et al., 2012), but their sig-
niﬁcance in regulating immunity to the liver-stage had not been
documented.
Such co-inhibitory signals should not be seen as an alterna-
tive explanation to the limitations placed on CD4+ T help by
constraints of cross-presentation and APC licensing. One strik-
ing example comes from virus hepatitis research, where the
“exhausted” state of anti-hepatitis B virus (HBV) CD8+ T cells
could be reversed by providing CD40, a key component of the
licensing mechanism (Isogawa et al., 2013). Typically, CD8+ T
cells in chronic HBV and HCV display all the features of exhaus-
tion, and in both cases there is a lack of CD4+ T cell activation.
An inclusive view is that the display of PD-1, Tim3, and Lag3 on
the exhausted CD8+ T cell may be a downstream consequence of
the inability to deliver CD4+ T cell help. In malaria, as in other
globally important liver pathogens, it will be most important to
understand whether this results from a failure of APC licensing,
or the failure of those mechanisms that have evolved as back-ups
in case licensing fails.
CONCLUSION
Liver-stage malaria parasites inside hepatocytes occupy a cell type
that can actively present antigen to MHC class I-restricted CD8+
T cells, but can neither directly activate CD4+ T cells, nor become
licensed through interaction with CD4+ T cells. Since CD4+ T
cell help is essential for full CD8+ T cell activation, function and
protective memory, it is critical that both non-speciﬁc danger sig-
nals (DAMPs) and pathogen-associated innate immune activators
(PAMPs) converge on an APC that can both cross-present anti-
gen to CD4+ T cells, and be licensed to fully activate CD8+ T
cells. In WT malaria infection, the parasite deftly subverts these
mechanisms, in part through exerting control over the timing and
mode of death of the infected cell. Successful experimentalmalaria
vaccine strategies involve liver-attenuated parasites that furnish
antigens, DAMPS and PAMPs, but fail to exert full control over
the death of the infected cell. More detailed understanding of these
mechanisms may lead to techniques to optimally deliver practi-
cal subunit vaccines, bringing CD4+ T cell help to anti-malaria
CD8+ T cells and resulting in long-lived protective immunity at
the liver-stage.
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